Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes With Specificities Against Tumor Associated Antigens During and After Neoadjuvant Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer

X
Trial Profile

Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes With Specificities Against Tumor Associated Antigens During and After Neoadjuvant Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 23 May 2018 Status changed from active, no longer recruiting to completed.
    • 26 Sep 2017 Primary endpoint (Percentage of subjects with detectable circulating T cells after treatment) has not been met, according to results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 26 Sep 2017 Results assessing effects of ipilimumab when added to neoadjuvant chemotherapy (paclitaxel + carboplatin + cisplatin) on levels of detectable circulating T cells with specificities against tumour-associated antigens (TAA) in patients with treatment-naive stage IB or II non-small cell lung cancer, were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top